Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus ONMEL.
COXANTO vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
1 g intravenous every 6 hours.
50 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category C
Category C
NSAID
NSAID